IFITM3-mediated activation of TRAF6/MAPK/AP-1 pathways induces acquired TKI resistance in clear cell renal cell carcinoma.
Se Un JeongJa-Min ParkSun Young YoonHee Sang HwangHeounjeong GoDong-Myung ShinHyein JuChang Ohk SungJae Lyun LeeGowun JeongYoung Mee ChoPublished in: Investigative and clinical urology (2024)
These results demonstrate IFITM3-mediated activation of the TRAF6/MAPK/AP-1 pathways as a mechanism of acquired TKI resistance, and suggest IFITM3 as a new target for TKI-resistant ccRCC.